☆
Watchlist
Log in
Sign-up
Opyl Ltd (opl) Logo

Opyl Ltd (OPL)

___:___ · Technology
0.00
0.00
(0.00)
VOLUME
DIV YIELD
PE RATIO
1 YR RETURN
52 WEEK RANGE
Overview
Financials (10-yr)

OPL Chart

Snapshot

OPL's Principal Activity is the development of digital tools that improve the healthcare experience for patients, deliver market insights from social media data and improve the efficiency and value of clinical research process.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume
Volume (4w avg)
Turnover
Open
Day Range -
VWAP
Prev Close
Last Trade

Performance

1 Week
1 Month
2022 YTD
1 Year
vs Sector (1yr) -49.66%
vs ASX 200 (1yr) -69.33%

Size

Market Cap Question Mark Icon
Excludes mandatory escrowed shares and foreign shares.
ASX Rank 2,354 of 2,408
Sector Rank 223 of 234

Key Fundamentals

Shares Issued
Sector Technology
Similar Companies RFN / TKF / KKL
EPS -$0.056
DPS $0.00
Book Value Per Share $0.04

Broker Consensus

OPL is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.

Top Market Index News

More News

Announcements

Date Heading Pages File Size Time

Corporate Overview

Opyl Limited (OPL, formerly ShareRoot Ltd) provides biopharma and health organisations access to emerging AI-assisted technologies and professional guidance to understand and improve healthcare design, development and delivery.

Incorporation Details

Incorporated in QLD on 15/01/1994. Changed its status from NL to Ltd on 21/02/2003.

Corporate Details

Head Office St Kilda VIC 3182
Website www.opyl.ai
Registry Automic Group
Auditor William Buck Audit (VIC) Pty Ltd
Date Listed 7 Mar 1996

Upcoming Calendar (Forecasted)

Date Event
26/08/2022 Report (Prelim)
26/08/2022 Report (Annual)
29/08/2022 Report (Prelim)
14/12/2022 Report (Annual)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.
Show All

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Dr Megan Robertson Non-Executive Director May 2021

Dr Megan Robertson

Non-Executive Director

Dr Robertson is the current Group Chief Research Officer at St Vincent's Health Australia and Director of Research at St Vincent's Hospital, Melbourne. She also works as a Senior Care Consultant at Epworth Healthcare (Richmond and Freemasons). She is on the boards of the Digital Health CRC, St Vincent's Institute of Medical Research, (PTSD-ANZ), Queen's College (University of Melbourne) and the Tuckwell Scholarship Selection Panel at ANU. She also works with national bodies including the Australian Commission on Safety and Quality in Healthcare, AusBiotech and the National Health and Medical Research Council. Previously, she held positions as the Director of Professional Affairs, CICM, as the Executive Director of Research at Epworth HealthCare and as the Co-Director of the Intensive Care Unit at Epworth Freemasons. She has led initiatives in the St Vincent's Research Directorate including the establishment of the St Vincent's Research Valet Service, development of the Victorian Clinical Trial Gateway portal, Clinical Trials Business Development model, facilitated research activities of the research Governance Unit, and built linkages between clinicians/researchers and industry, as well as linkages between clinicians/researchers and community.
Mr Mark Ziirsen Non-Executive Director Sep 2020

Mr Mark Ziirsen

Non-Executive Director

Mr Ziirsen is an experienced ASX listed, non-executive director and CFO. He served as non-executive director and chair of Respiri Limited, an eHealth SaaS company supporting respiratory health management, and as non-executive director and chair of the Audit and Risk Committee of Orcoda Limited, a SaaS-based technology company. His executive career includes senior finance leadership roles with major ASX listed companies including Cochlear Limited, Aristocrat Leisure Limited, CocaCola Amatil Limited and Goodman Fielder Limited. He commenced his career with EY in business advisory, tax and management consulting. Most recently, he was CFO and company secretary for Wiseway Group Limited. Immediately prior to that he was CFO of listed global medtech company Anteris Technologies Limited and before that, Director of Finance and IT for Asia Pacific at hearing implant maker Cochlear Limited.

Mr David Lilja Company Secretary Dec 2019
Dr Julian John Chick Non-Executive Director May 2019

Dr Julian John Chick

Non-Executive Director

Mr Chick has more than 25 years of experience in the biotechnology and medical technology industry as well as five years in investment banking. Julian's previous roles include investment adviser, healthcare analyst for private equity investors, portfolio manager, investment banker and venture capitalist. Julian has developed a number of technologies from discovery through to market as well as numerous capital raisings, M&A transactions, company restructuring, business development and licensing transactions.
Ms Michelle Gallaher Chief Executive Officer Mar 2019
Mr Damon Rasheed Executive Director Feb 2019

Mr Damon Rasheed

Executive Director

Mr Rasheed has more than 20 years of experience in the tech sector, including founding several start-ups. He is the founder of Rate Detective Group, financial comparison websites. He is also the co-founder of Advantage Data, a machine learning and AI consultancy business. His most recent venture is Aurum Data which has built a propriety AI model to value data and discover commercialisation strategies for data sets. He has sat on the boards of several private technology companies both in Australia and overseas. Damon's former roles include CEO of iBus Media Limited.
Show All

Director Transactions

OPL directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
10/03/22 Julian Chick Buy +138,088 $0.075 $10,356 On-market trade
09/02/22 Mark Ziirsen Buy +67,500 $0.096 $6,480 On-market trade
24/12/21 Megan Robertson Buy +46,901 $11.50 $539,361 On-market trade
30/11/21 Julian Chick Buy +100,000 $0.11 $11,000 On-market trade
25/11/21 Damon Rasheed Buy +70,000 $0.115 $8,050 On-market trade
23/11/21 Julian Chick Buy +73,500 $0.143 $10,495 On-market trade
17/06/21 Marat Basyrov Transfer 802,000 $0.19 $152,380 Off-market transfer
17/06/21 Marat Basyrov Transfer 802,000 $0.19 $152,380 Off-market transfer
26/04/21 Julian Chick Buy +150,000 $0.15 $22,500 Participation in share purchase plan
26/04/21 Damon Rasheed Buy +80,400 $0.15 $12,060 Participation in share purchase plan
18/01/21 Damon Rasheed Buy +42,267 $0.165 $6,974 On-market trade
08/09/20 Damon Rasheed Buy +30,000 $0.194 $5,820 On-market trade
23/06/20 Julian Chick Buy +222,222 $0.09 $19,998 On-market trade
03/12/19 Julian Chick Buy +103,274 $0.141 $14,537 On-market trade
15/10/19 Damon Rasheed Buy +4,000,000 $0.002 $8,000 On-market trade
14/10/19 Julian Chick Transfer 4,033,333 $0.002 $8,067 Off-market transfer
14/10/19 Julian Chick Transfer 4,033,333 $0.002 $8,067 Off-market transfer
14/10/19 Julian Chick Buy +9,891,196 $0.002 $19,782 On-market trade
19/07/19 Julian Chick Issued 1,613,333 $0.001 $1,613 Rights issue
Show All

Director Interests

The current holdings of OPL directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Julian Chick 10/03/2022 0 926,329 484,998 N/A
Mark Ziirsen 09/02/2022 67,500 N/A 300,000 N/A
Megan Robertson 24/12/2021 0 46,901 N/A N/A
Damon Rasheed 25/11/2021 262,667 N/A 429,998 N/A
Show All

Shareholder Info

Top 20 Shareholders
About the Data

Data supplied by Morningstar and accurate on Jul 15, 2021.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
UBS Nominees Pty Ltd 2,749,696 5.06%
Scintilla Strategic Investments Limited 1,735,946 3.19%
Altor Capital Management Pty Ltd (Altor Alpha Fund A/C) 1,550,000 2.85%
Celerity Investments Pty Limited 1,362,462 2.51%
Kyriaco Barber Pty Ltd 1,325,000 2.44%
Hongkong Frank Pty Ltd (Davis Super Fund A/C) 1,250,000 2.30%
Pickard Capital Pty Ltd 1,000,000 1.84%
Pickard Capital Pty Ltd (i) 975,000 1.79%
Mr Duncan Gerard Gowans & Mrs Jodie Louise Gowans (GowansSuperfund A/C) 860,000 1.58%
Supertank Pty Ltd (Supertank Superfund A/C) 860,000 1.58%
Rewop Pty Ltd (Scott Power Super Fund A/C) 840,669 1.55%
Mr Firdaus Basyrov 802,000 1.47%
Kamarel Pty Ltd (K F & M L Smith S/F A/C) 689,810 1.27%
Dr Derek Anthony Jellinek 683,153 1.26%
Mrs Anna Carina Hart & Mr Paul Hart (Hart Family Super Fund A/C) 638,298 1.17%
Mr Elie Chakkour 600,000 1.10%
Jaloo Pty Limited (G W Super Fund No 1 A/C) 600,000 1.10%
Stone Cold Capital Pty Ltd 528,110 0.97%
Mr Robert Gareth Price & Mr Steven David Price (Simest Super Fund A/C) 506,150 0.93%
Dr Thomas Peter Clarke & Mrs Gilda Frances Clarke (Tp&Gf Clarke Super Fund A/C) 500,000 0.92%
Show All

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 86 212 161 308 110 877

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
Ubs Nominees Pty Ltd 15/07/2021 2,749,696 5.06

Shareholders Buying

12 month transaction history compiled from ASX announcements.

No buy transactions reported by Substantial Shareholders in the past 12 months.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2021 $0.18 30 June
2020 $0.087 30 June
OPL Historical Price Data (CSV)
Up to 20 years of EOD share price history
Sign up to Download
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.